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Abstract
Objective—To evaluate the existing literature on psychological, social, and behavioral aspects of
chronic hepatitis C viral (HCV) infection and antiviral treatment; provide the state of the
behavioral science in areas that currently hinder HCV-related health outcomes; and make
recommendations for areas in which clinical psychology can make significant contributions.
Methods—The extant literature on HCV and antiviral therapy was reviewed as related to
biopsychosocial factors such as mental health, substance/alcohol use, quality of life, coping,
stigma, racial disparities, side effects, treatment adherence, integrated care, and psychological
interventions.
Results—For reasons that have not been well elucidated, individuals infected with HCV
experience psychological and somatic problems and report poor health-related quality of life.
Preexisting conditions, including poor mental health and alcohol/substance use, can interfere with
access to and successful completion of HCV treatment. Perceived stigma is highly prevalent and
associated with psychological distress. Racial disparities exist for HCV prevalence, treatment
uptake, and treatment success. During HCV treatment, patients experience exacerbation of
symptoms, treatment side effects, and poorer quality of life, making it difficult to complete
treatment. Despite pharmacological advances in HCV treatment, improvements in clinical and
public health outcomes have not been realized. The reasons for this lack of impact are
multifactorial, but include suboptimal referral and access to care for many patients, treatment-
related side effects, treatment nonadherence, and lack of empirically-based approaches.
Conclusions—Biomedical advances in HCV and antiviral treatment have created a fertile field
in which psychologists are uniquely positioned to make important contributions to HCV
management and treatment.
Keywords
Interferon; Psychosocial; Coping; Adherence; Multidisciplinary
Correspondence: Donna Evon, PhD, Division of Gastroenterology and Hepatology, CB# 7584, University of North Carolina, Chapel
Hill, NC 27599-7584. Donna_Evon@med.unc.edu.
Potential Competing Interests: Drs. Golin and Keefe have nothing to disclose.
NIH Public Access
Author Manuscript
J Consult Clin Psychol. Author manuscript; available in PMC 2014 April 01.
Published in final edited form as:














Chronic hepatitis C viral (HCV) infection is a global health epidemic that has gained recent
attention from national and global health organizations (Institute of Medicine, 2010;
U.S.DHHS, 2011). HCV slowly attacks the liver, advancing to cirrhosis or liver cancer in
20% of cases, and leads to significant mortality. HCV is transmitted through exposure to
contaminated blood, with 60% of cases acquired via injection drug use or blood transfusions
administered before 1992; less frequently, transmission occurs through occupational
exposure, hemodialysis, and vertical transmission, and rarely through sexual contact (Alter
et al., 1999; Armstrong et al., 2006). The interplay amongst several biopsychosocial factors,
antiviral treatment, and health outcomes is extremely complex and warrants attention from
clinical psychologists. This article reviews evidence for the role that psychological, social,
and behavioral factors play in HCV health outcomes and the implications this has for future
research initiatives to optimize HCV care and treatment. As a narrative review, and not a
systematic or meta-analytic review, limitations such as the potential for bias are noted.
Figure 1 provides an overview of biopsychosocial factors that, if present before and during
treatment, may affect HCV outcomes. A high prevalence of premorbid psychological
conditions and alcohol/substance use often exist for years prior to HCV diagnosis. Due to
these conditions, patients are often deferred from HCV treatment due to concerns that
treatment will worsen preexisting psychological conditions or that such preexisting
comorbidities will interfere with treatment adherence. Some individuals with HCV report
multiple pre-treatment somatic and psychological symptoms, including fatigue, insomnia,
depression, and bodily pain.
Patients often struggle to adjust to and cope with HCV, HCV-related stigma, and a lower
health-related quality of life (HrQOL) relative to the general population (Bondini et al.,
2007; Foster, Goldin, & Thomas, 1998; Spiegel et al., 2005). Clinical observations suggest a
bi-directional relationship between the existence of biopsychosocial factors before treatment
and the emergence of side effects and lower HrQOL during treatment. Biopsychosocial
factors may influence the ability to cope with treatment side effects, while such side effects
exacerbate preexisting symptoms and further impair precarious health. Moreover, protease
inhibitor medications, recently approved to treat HCV, require patients to follow an
intensive dosing schedule that can lead to viral resistance if not followed closely. Preexisting
and treatment-induced conditions can hinder adherence to the treatment protocol: patients
may miss doses, require dose reductions, or discontinue treatment prematurely, each of
which impedes virologic cure. Conversely, eradicating HCV improves HrQOL, work
productivity, disease control, and reduces morbidity and mortality (Ikegami et al., 2009;
McHutchison et al., 2001; Spiegel et al., 2005; U.S.DHHS, 2011).
Empirically-based practices are needed to help patients access and complete this potentially
life-saving treatment. Researchers with expertise in mental health, alcohol/substance use,
coping skills, HrQOL, stigma, and health behavior change can improve knowledge of the
complex interplay between biopsychosocial factors and HCV health outcomes. Such
knowledge can inform development and evaluation of interventions to enhance coping
skills, disease- and side-effect management, and medication adherence to improve health
outcomes. To delineate these potential contributions, implications for psychosocial and
behavioral research which are likely to produce significant gains in HCV outcomes, are
provided throughout and at the end of the paper.
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HCV Epidemiology and Impact on Public Health
Chronic HCV is a global public-health problem affecting 130 million people worldwide,
including over 3.2 million Americans (Armstrong et al., 2006). HCV-related cirrhosis and
liver cancer lead to 10,000 deaths each year in the U.S., and are the leading indications for
liver transplant (Shepard, Finelli, & Alter, 2005). HCV also causes extrahepatic conditions,
such as autoimmune syndromes of the kidneys, skin, mouth, eyes, and musculoskeletal
system. A fourfold increase in the prevalence of HCV complications by 2030 is expected
due to aging of a large number of infected Baby Boomers (Davis, Alter, El-Serag, Poynard,
& Jennings, 2010). These projections suggest that HCV will lead to significant public health
and economic burdens over the next 20 years unless more individuals successfully undergo
antiviral treatment.
Antiviral Treatment for HCV
The goal of antiviral therapy is to permanently eradicate HCV. A person is considered cured
if they achieve a sustained virologic response (SVR), defined as undetectable HCV RNA six
months post-treatment (Ghany, Strader, Thomas, & Seeff, 2009). As Figure 1 illustrates,
achieving SVR is the primary outcome of treatment and is associated with improvements in
HrQOL (vitality, social functioning, health distress, HCV-specific distress), fatigue, work
functioning and productivity, reduced liver inflammation, prevention of disease progression,
improved survival, and control of the spread of HCV (Backus et al., 2011; Ikegami et al.,
2009; McHutchison et al., 2001; Spiegel et al., 2005; World Health Organization, 1999).
Interferon-based antiviral regimens have been approved for HCV for 15 years. Until 2011
the treatment of choice was a combination of injectable pegylated interferon (IFN) and oral
ribavirin (RBV) for 24 or 48 weeks, depending on genotype (i.e., viral strain). IFN is an
endogenous proinflammatory cytokine that is naturally produced by the body in response to
infection and inflammation; when given exogenously, it mimics the body’s activation of the
immune system. Proinflammatory cytokines, including those naturally occurring as well as
used in medical treatments, are associated with neuropsychiatric symptoms in humans and
sickness behavior in animals(Raison, Demetrashvili, Capuron, & Miller, 2005b). During
treatment for HCV, patients self-inject IFN weekly and take RBV tablets twice daily.
Patients infected with genotype 1 HCV (75%) required 48 weeks of treatment for a 40–50%
chance of SVR, while patients infected with genotype 2 or 3, required 24 weeks of treatment
for a 70–85% chance of SVR (Fried et al., 2002).
In 2011, two protease inhibitors were approved for use in combination with IFN/RBV for
patients with genotype 1. This “triple therapy” regimen boasts SVR rates of 68–75%, a
substantial improvement over SVR rates during IFN/RBV therapy (Jacobson et al., 2011;
Poordad et al., 2011). Moreover, treatment duration may be decreased from 48 to 24 weeks.
Like the protease inhibitors introduced for HIV 15 years ago, triple therapy presents patients
with new challenges for medication adherence (i.e., increased toxicity, more frequent
dosing, and development of viral resistance under conditions of suboptimal adherence).
Triple therapy is the current standard of care for patients with genotype 1 and will remain as
such for several years.
Since approval of triple therapy last year, new oral drugs, including “IFN-free” multi-drug
regimens, have been in development. In the future, such regimens may hopefully lead to
curing more people, although as we have learned from the fight against HIV, behavioral,
psychosocial, and environmental factors may ultimately be the issues that thwart worldwide
obliteration of HCV.
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As Figure 1 depicts, psychosocial factors before treatment have a bi-directional relationship
with on-treatment factors, and can also directly affect adherence to the treatment protocol,
which, in turn, affects SVR. Several biomedical factors also directly affect SVR.
Premorbid Mental Health and Substance and Alcohol Use Issues
Mental health and substance/alcohol abuse represent the most significant patient-level
barriers to optimal HCV care. Premorbid psychiatric and substance use disorders are highly
prevalent in the HCV population, with a 40% one-month prevalence and greater than 80%
lifetime prevalence (Dwight et al., 2000; El-Serag, Kunik, Richardson, & Rabeneck, 2002).
These conditions can adversely affect diagnosis, referral, eligibility, and treatment outcomes
(Ho et al., 2001; Leutscher et al., 2010; Volk, 2010). Patients with these conditions are less
likely to engage in, or have less access to, routine healthcare where HCV screening and
diagnosis occur (Evon et al., 2010). Those with active psychiatric and addiction disorders
may be less likely to be referred to a specialist at diagnosis (Zickmund, Brown, & Bielefeldt,
2007). Even if such referrals are issued, these comorbidities are the most common reasons
HCV specialists defer treatment (Evon et al., 2007). While several barriers to HCV care
exist, improving mental health and reducing alcohol/substance use are fundamental paths
through which psychological interventions can enhance HCV health outcomes. While
barriers to HCV treatment are being removed, practice guidelines would gain considerably
more traction if HCV care was integrated with mental health/substance use protocols (Evon
et al., 2011). Healthcare reform, and support from funding agencies and insurance
companies, is needed to support the practice and evaluation of empirically-based integrated
care approaches.
Premorbid mental health issues—The broad term “mental health” is deliberately used
here to encompass psychiatric disorders, as well as the frequently observed emotional
distress of HCV patients, which cannot be fully appreciated by a mere diagnosis. Though
accurate psychiatric diagnoses are also important, significant emotional distress observed by
providers in the clinical setting is just as likely to influence decisions regarding treatment
candidacy.
Patients with HCV not on treatment report many emotional disturbances, including
depressive symptoms (70%) and irritability (74%) (Lang et al., 2006). A quarter of HCV
patients meet diagnostic criteria for current major depression, 36% meet criteria for lifetime
depression, and up to 70% report some level of depression (Dwight et al., 2000; Golden,
O'Dwyer, & Conroy, 2005; Raison et al., 2005b). Anxiety, irritability, and hypomania have
not been studied as systematically, but are important to identify and stabilize before
treatment to prevent management challenges that can result in terminating treatment
(Lotrich, Ferrell, Rabinovitz, & Pollock, 2010; Rifai, 2006; Russo et al., 2005).
Based on concerns that IFN treatment for HCV could worsen psychiatric symptoms, initial
treatment guidelines discouraged treatment for patients with unstable psychological
conditions. However, based on ample evidence, the guidelines were eventually modified to
indicate that treatment “can be safely administered, provided there is comprehensive
pretreatment psychiatric assessment, a risk benefit analysis, and provisions for ongoing
follow-up of neuropsychiatric symptoms during antiviral therapy by a multidisciplinary
team” (Ghany et al., 2009, p. 1362). Clearly, the development and evaluation of
multidisciplinary treatment protocols are needed to achieve these practice guidelines.
Premorbid substance use—Many individuals with HCV have lifetime histories of
substance use disorders (36– 66%) (Edlin, 2002). Intravenous drug use is the primary mode
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of acquisition, with 70–90% of current injection drug users estimated to be infected (Edlin,
2002; Sulkowski & Thomas, 2005). Observational studies find that illicit drug users can
safely undergo and adhere to the treatment regimen and achieve good SVR rates, as long as
treatment is delivered within multidisciplinary or integrated care settings (e.g., methadone
clinics) (Dore et al., 2010; Grebely et al., 2010; Sylvestre et al., 2004; Sylvestre & Clements,
2007; Zanini, Covolo, Donato, & Lanzini, 2010). Notably, a meta-analysis found that
multidisciplinary teams were more efficacious when psychologists (as opposed to
psychiatrists or addiction specialists) were part of the team(Zanini et al., 2010). This finding
highlights the need to identify the specific strategies employed by multidisciplinary teams
that are associated with treatment success.
Current HCV guidelines encourage careful consideration of the risks and benefits of treating
active illicit drug users, and state that ideally “HCV management is integrated with
addiction treatment and delivered by multidisciplinary teams, including experienced drug
abuse and psychiatric counseling services” (Ghany et al., 2009, p. 1361). In theory, the
guidelines do not view active drug use as an absolute contraindication to treatment;
however, in reality, very few active drug users undergo HCV treatment. Patient
characteristics (e.g., low perceived severity) and social factors (e.g., unstable housing) are
associated with nontreatment of drug users (Lally, Montstream-Quas, Tanaka, Tedeschi, &
Morrow, 2008; Mehta et al., 2007). Provider-level beliefs and attitudes likely play an
important role in treatment decision-making, but have yet to be investigated.
Several gaps in current knowledge require the attention of behavioral and social scientists.
Studies have not distinguished outcomes among subgroups of drug users, even among those
who inject drugs, snort cocaine, or smoke marijuana. Moreover, specific patient or drug use
characteristics (e.g., type or frequency) that predict poor treatment outcomes have rarely
been identified (Sylvestre & Clements, 2007). Finally, the efficacy of multidisciplinary
treatment models or psychological treatments for HCV+ drugs users have not been formally
tested in clinical trial methodology; therefore, no empirically-based protocols exist. As such,
practice guidelines and evidence-based, tailored strategies for different subgroups are not
available to guide the selection and management of reasonable treatment candidates. These
gaps in the literature result in nontreatment of a vast majority of individuals, many of whom
may be capable of safely adhering to the treatment regimen. Recent studies indicate that
providing HCV treatment to injection drug users is highly cost-effective; however a lack of
multidisciplinary treatment infrastructure to engage and treat these individuals contributes to
nontreatment(Martin et al., 2012). Extensive healthcare and policy reform, including
innovative treatment delivery protcols, will be needed to expand treatment to those with
addiction comorbidities.
Premorbid alcohol use—Alcohol use and HCV often coexist, with a prevalence of HCV
up to 30 times higher in persons with alcohol use disorders (Anand et al., 2006; Dieperink et
al., 2010; Singal & Anand, 2007). Excess alcohol is an independent risk factor for
development and progression of liver disease, works synergistically with HCV to advance
liver disease, and allows HCV to replicate more rapidly (Nishiguchi et al., 1991; Poynard,
Bedossa, & Opolon, 1997; Romero-Gomez et al., 2001; Singal & Anand, 2007; Wiley,
McCarthy, Breidi, McCarthy, & Layden, 1998). Excess alcohol consumption during
treatment is associated with lower SVR rates owing to immunosuppression or nonadherence
(Anand et al., 2006; Singal & Anand, 2007).
The amount of alcohol that is safe for persons with HCV remains controversial. Moderate to
heavy daily consumption is widely considered unsafe, is associated with liver damage, and
reduces treatment efficacy (Ghany et al., 2009; Pessione et al., 1998; Westin et al., 2002).
However, mild alcohol use (<30 grams/day) may not be associated with advancing liver
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disease or worse SVR rates (Anand et al., 2006; Bruggmann, Dampz, Gerlach, Kravecz, &
Falcato, 2010; Cheung et al., 2011). Hence, recommendations for alcohol abuse counseling
for heavy alcohol consumers are empirically-driven, but those for lighter drinkers are not,
until more data are obtained. The lack of data and the consequent vagueness of practice
guidelines leads to idiosyncratic physician decisions and mixed messages for patients
(Blixen et al., 2008). Interventions to reduce excess alcohol consumption are needed. Brief
physician-delivered protocols or co-location of addiction counselors in liver clinics show
promise (Dieperink et al., 2010; Proeschold-Bell et al., 2011), but efficacy and cost-
effectiveness have not been evaluated.
Health-related Quality of Life and HCV-related Symptoms
HCV is associated with significant reductions in patients’ health-related quality of life
(HrQOL) compared to the general population, and even to patients with hepatitis B (Bondini
et al., 2007; Foster et al., 1998; Spiegel et al., 2005). Most studies have used the SF-36
health survey to measure functional health status, defined as the extent to which patients can
perform normal daily activities without interference from health problems(McHutchison et
al., 2001; Spiegel et al., 2005; Ware, Jr., Bayliss, Mannocchia, & Davis, 1999). Studies
generally find that the largest mean differences between HCV patients and the general
population are on vitality, role-physical, role-emotional, and general health scales, as well as
on the mental composite score (Spiegel et al., 2005). The etiology of HrQOL disparities is
complex and not well understood. HrQOL is not related to liver disease severity (except in
those with cirrhosis); however it has been associated with HCV-related symptoms (e.g.,
fatigue, depression), comorbid conditions, perceived stigma, or knowledge of having HCV
(Dan et al., 2006; Fontana et al., 2005; Foster et al., 1998; Kallman et al., 2007; Lang et al.,
2006; Younossi, Kallman, & Kincaid, 2007; Zickmund, Ho, Masuda, Ippolito, &
LaBrecque, 2003). The effect of drug abuse history on HrQOL is equivocal (Foster et al.,
1998). Fortunately, eradication of HCV through antiviral therapy is associated with
improvements in HrQOL (e.g., vitality, social functioning, health distress, work functioning,
and productivity)(McHutchison et al., 2001; Ware, Jr. et al., 1999).
HCV-related Stigma
Societal stigma has been defined as a “mark” that is deeply discrediting and ruins “the
marked person’s normal identity” (Goffman, 1963). Societal stigma can exist for many
human conditions, but infectious diseases (e.g., HIV), mental illness, drug addiction, and
alcoholism carry particularly strong societal stigma (Paterson, Backmund, Hirsch, & Yim,
2007). By association, HCV has great potential to be a highly stigmatized illness.
The HIV Stigma Framework provides a conceptual model that can be applied to HCV to
understand how individuals experience stigma and the mechanisms by which societal stigma
affects HCV outcomes (Earnshaw & Chaudoir, 2009). The model suggests that societal
stigma elicits stigma mechanisms, which, in turn, can have deleterious outcomes. Stigma
mechanisms are the ways in which individuals react psychologically to knowledge that they
possess the “mark” and include: (a) enacted stigma (experience of prejudice and
discrimination); (b) anticipated stigma (expectations of future prejudice and discrimination);
and (c) internalized stigma (endorsement of negative beliefs and feelings about themselves).
These stigma mechanisms, in turn, may negatively affect psychological, behavioral, and
social outcomes.
A review of 21 mostly qualitative studies on HCV-related stigma suggests that 22–100% of
study participants perceived stigma related to HCV (Paterson et al., 2007). Moreover, most
authors concluded that this stigma is due to association with drug use, alcoholism, HIV,
sexually transmitted diseases, and sexual promiscuity (Butt, 2008; Butt, Paterson, &
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McGuinness, 2008; Sgorbini, O'Brien, & Jackson, 2009; Zickmund et al., 2003).
Importantly, while patients report HCV-related stigma during interactions with healthcare
workers, family, and co-workers (Butt, 2008; Paterson et al., 2007; Richmond, Dunning, &
Desmond, 2004), only one study has evaluated actual stigmatization toward people with
HCV(van de Mortel, 2002).
Evidence from HCV stigma studies are consistent with the HIV Stigma Framework, which
purports that enacted, anticipated, and internalized stigma are mechanisms by which societal
stigma affects outcomes. For example, anticipated HCV stigma leads to frequent worry
about HCV “being discovered” (Schafer, Scheurlen, Felten, & Kraus, 2005). Up to 25% of
patients report nondisclosure of HCV to friends, and 55% report nondisclosure to
physicians. Patients also report internalized stigma such as shame (66%) and insecurity
(63%), and fear of contaminating others leads to unnecessary behaviors like not sharing
drinking cups or food, and inhibiting dating or sexual activity (Zacks et al., 2006). Finally,
stigma is associated with poorer psychological well-being (i.e., depression, anxiety, anger,
difficulty coping, feelings of loss of control) (Golden, Conroy, O'Dwyer, Golden, &
Hardouin, 2006; Zacks et al., 2006; Zickmund et al., 2003). Future studies would benefit
from applying theoretical models like the HIV Stigma Framework to investigate moderators,
mediators, and consequences of HCV-related stigma.
Appraisal of and Coping with HCV
As a stigmatized disease with psychological and social ramifications and an uncertain
prognosis, HCV has the potential to be an extremely stressful illness. According to Lazarus
and Folkman’s cognitive appraisal theory, individuals diagnosed with HCV would first
assess the threat or harm of HCV (primary appraisal), and then the availability and
effectiveness of internal and external resources to aid coping (secondary appraisal) (Lazarus
& Folkman, 1984).
Very few substantive articles address coping with HCV. Although roughly 25 articles exist,
most are case studies, editorials, or qualitative studies that are not amenable to statistical
analysis and interpretation. Eight cross-sectional survey studies have described elements of
appraisal or coping, but were ancillary to primary study aims. Nevertheless, broad themes
that emerge from existing data can serve to generate hypotheses for more methodologically
rigorous studies in HCV coping.
The extant literature suggests that individuals diagnosed with HCV appraise the illness as
quite threatening (Blacklaws et al., 2009; Grassi et al., 2002; Sgorbini et al., 2009; Sutton &
Treloar, 2007). In one study (N=185), patients appraised HCV as a “74” out of 100 on a
disease severity scale (Constant et al., 2005). The appraisal of HCV may be moderated by
several variables that require further scrutiny: (a) age (e.g., older age may be associated with
worse illness perceptions); (b) history of injection drug use may be associated with less
perceived threat; (c) personality traits (e.g., sense of coherence and attentional style are
associated with coping styles); (d) gender (e.g., women may appraise HCV as more
threatening due to fear of transmission to family); and (e) co-infection (e.g., men who have
sex with men may view HCV as more threatening than HIV due to stigma and may be less
willing to disclose HCV status) (Erim et al., 2010; Grundy & Beeching, 2004; Miller,
Rodoletz, Mangan, Schroeder, & Sedlacek, 1996; Owen, 2008).
Patients with HCV may employ a variety of coping strategies. One study (N=264) found that
the most used coping strategies were behaviorally-oriented (70%), followed by engagement
in medical care (62%), and finally by cognitive and religious coping strategies (34%)
(Stoller et al., 2009). People who coped behaviorally reported changing diets (44%),
activity-rest cycles (17%), and hygiene practices (12%). Cognitive strategies included
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acceptance, compartmentalization, and downward social comparisons. Other studies report
use of prayer and forms of relaxation (Kinder, 2009; Richmond, Bailey, Jr., McHutchison, &
Muir, 2010). Coping strategies may be moderated by a number of factors. Older patients
may be more likely to use religious coping; patients recently diagnosed with HCV may
engage in more active, problem-solving coping compared to those diagnosed longer ago;
and those with more advanced liver disease may use less adaptive coping than those with
less advanced disease (Kraus, Schafer, Csef, Scheurlen, & Faller, 2000; Miller et al., 1996).
With the exception of one quantitative study, no studies have examined the relationship
between coping strategies and psychosocial outcomes (Richmond et al., 2010). As such,
quantitative studies, especially those utilizing reliable and validated psychological
instruments to strengthen internal validity, are needed.
Our clinical experience mirrors findings that patients actively cope by making positive
lifestyle changes. In addition to quitting alcohol and drugs, it is common for patients to eat
healthier, use herbal supplements, quit smoking, increase activity, and reprioritize life goals
(Paterson, Butt, McGuinness, & Moffat, 2006; Sgorbini et al., 2009; Sutton & Treloar,
2007). As such, receiving a diagnosis of HCV and preparing for treatment may thus serve as
potent “teachable moments”—naturally occurring health events that motivate people to
make positive lifestyle changes (McBride, Emmons, & Lipkus, 2003).
Racial Disparities in HCV Prevalence, Treatment Uptake and Treatment Efficacy
It is important for clinical psychologists working with HCV patients to appreciate significant
racial health disparities that exist between African Americans (AAs) and Caucasian
Americans (CAs). HCV is 2–3 times more prevalent among AAs (3.2%) compared to CAs
(1.5%), yet AAs are much less likely to be referred for specialty HCV care (32% vs. 71%,
respectively) (Alter et al., 1999; Armstrong et al., 2006; Kanwal et al., 2007; Kramer et al.,
2010; Trooskin et al., 2007). Even in clinical drug trials which provide medical treatment at
no expense, less than 10% of participants are AA (Fried et al., 2002; McHutchison et al.,
2009b; McHutchison et al., 2009a). While preexisting medical conditions (e.g., neutropenia,
diabetes, renal insufficiency) may partially explain why AAs are excluded from drug trials
(Melia et al., 2011), psychosocial factors may also influence racial differences in screening,
referral, and treatment uptake, including those at the patient (e.g., health beliefs, medical
mistrust), provider (e.g., knowledge, experience) and societal (e.g., access to care, insurance
status) levels, but these have rarely been explored (Kanwal et al., 2007; Kramer et al., 2010).
Moreover, preexisting medical conditions that exclude AAs from treatment (e.g., diabetes)
are modifiable through behavioral changes which could, in turn, enhance HCV treatment
eligibility and success for AAs.
Most important, AAs who undergo HCV treatment have much lower rates of SVR (20–
28%) compared to CAs (40–55%) (Conjeevaram et al., 2006; Fried et al., 2002; Muir et al.,
2011). Recently, the genetic polymorphism IL28B, a marker of IFN sensitivity, was found to
explain about half of the racial differences in SVR (Ge et al., 2009; Thompson et al., 2010).
Other variables that have been examined—educational status, body mass index, diabetes,
and medication adherence—do not account for racial disparities in SVR, and more data are
needed (Conjeevaram et al., 2006; Howell et al., 2008).
Health psychologists who care for individuals infected with HCV need to be aware of these
disparities to help patients process health beliefs, make informed decisions about treatment,
and cope with the disappointment associated with less favorable cure rates for many AAs.
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As shown in Figure 1, several biomedical factors are directly associated with treatment
outcomes and thus are important for both patients and providers to consider (Conjeevaram et
al., 2006; Conjeevaram et al., 2007; Thompson et al., 2010). While several of these variables
are immutable, others such as body mass index and diabetes control, are modifiable through
health behavior change. Collectively, these biomedical factors may account for over 50% of
the variance in treatment outcomes (Ge et al., 2009). Psychosocial factors that could account
for some of the remaining variance have not been well studied. Health psychologists
working closely with HCV providers can help educate patients about chances of cure,
carefully weigh the risks of treatment (e.g., worsening of HrQOL, depression, risk of
relapse) with potential benefits, and assist in making lifestyle modifications to increase the
odds of being cured.
Another biomedical factor that warrants brief discussion is co-infection with HIV and
hepatitis A and B, which can complicate treatment and health outcomes (Ghany et al.,
2009). More than 200,000 patients with HIV are also co-infected with HCV (Brau et al.,
2002; Singal & Anand, 2009). Liver disease has emerged as a leading cause of HIV-related
mortality (Soriano et al., 2011). Antiviral therapy is also less effective in HCV/HIV patients
(20–38%) compared to HCV-infected patients (54%), possibly due to higher rates of side
effects and premature discontinuations (Cooper, Giordano, Mackie, & Mills, 2010; Singal &
Anand, 2009; Sulkowski et al., 2004). HCV treatment uptake is also quite low (10–38%) in
HCV/HIV patients, perhaps due to concerns about additional side effects and the challenge
of juggling multiple medications (Wagner et al., 2009). These patient concerns could be
reviewed in psychologist-patient interactions or through HCV/HIV support or peer-led
groups (Grebely et al., 2010).
On-Treatment Factors
Treatment-related Side Effects
IFN-based treatment is well known to induce flu-like, neuropsychiatric, gastrointestinal and
other treatment-related side effects: fatigue (55%), headaches (50%), bodily pain (45%),
depressive symptoms (20–40%), insomnia (38%), and irritability (26%) (Bonaccorso et al.,
2001; Fried, 2002; Fried et al., 2002). Depression is the most concerning side effect due to
the high incidence of premorbid depression, potential for worsening during treatment, and
though rare, has been associated with suicide during treatment (Dieperink et al., 2004).
Depression is also one of the leading causes of treatment discontinuations and dose
reductions (Fried, 2002; Fried et al., 2002; McHutchison, Bacon, & Owens, 2007).
Medically-necessary treatment discontinuations also occur for anemia, neutropenia, and
other medical conditions (Fried et al., 2002).
Many treatment-related side effects may be amenable to treatment by psychological
interventions in three ways. First, early somatic/neurovegetative symptoms (fatigue,
insomnia, aches and pains, headaches) seem to precede and predict changes in cognitive-
affective depressive symptoms occurring later in treatment (Robaeys et al., 2007; Wichers,
Koek, Robaeys, Praamstra, & Maes, 2005). Thus, early psychological interventions aimed at
coping with somatic symptoms may reduce the development of full-blown major depression
later in treatment. Second, because many patients report preexisting symptoms that are
exacerbated during treatment, psychological interventions before HCV treatment may
improve symptom management before and during treatment, leading to better outcomes.
Finally, our clinical experience suggests that patients complain of mild to moderate
symptom clusters (e.g., fatigue-insomnia-depression-bodily pain) that take an insidious toll
on life functioning, as opposed to one severe side effect. This clinical observation is
consistent with studies in other medical populations that have observed a pain-depression-
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fatigue symptom cluster and has been associated with elevations in neuroendocrine markers
(Thornton, Andersen, & Blakely, 2010). The recent interest in symptom clustering
associated with hyperarousal of the sympathetic nervous system and hypothalamic-pituitary-
adrenal axis dovetails nicely with psychoneuroimmunological research in HCV exploring
interferon’s role as a proinflammatory cytokine in induction of the inflammatory response
system and manifestation of sickness behavior by patients during HCV treatment(Charlton,
2000; Maes, 2011; Raison et al., 2005a; Wichers & Maes, 2002). These findings suggest that
pre-treatment interventions aimed at stress management and coping with somatic symptoms
could improve psychological and physiological indices of stress, leading to better treatment
outcomes.
Worsening of Health-related Quality of Life
HrQOL deteriorates during HCV treatment for reasons that are multifactorial but largely
related to treatment-related side effects and poor health status (Younossi et al., 2007).
HrQOL may also diminish during treatment for reasons unrelated to side effects.
Undergoing HCV treatment can conjure feelings of guilt and shame or the idea that
treatment is penance for past indiscretions (Zacks et al., 2006). Patients may attempt to keep
treatment a secret from others, which leads to social isolation, or may experience enacted
stigma upon disclosure to others (Sgorbini et al., 2009). Patients report difficulties relating
to their partners and fulfilling parental duties (Sgorbini et al., 2009). Treatment may cause
significant financial burden due to missed work, insurance bills, and travel expenses related
to obtaining treatment in a specialty clinic, which could be hours away. Finally, patients tire
of the intensive pill burden, injectable medications, and rigorous appointment schedules.
These psychosocial factors may contribute to worsening HrQOL during treatment.
Rapid or Early Virological Response
Two robust predictors of SVR are rapid virological response (undetectable virus at treatment
week 4) and early virological response (undetectable virus at week 12) (Idrees & Riazuddin,
2009; Rodriguez-Torres et al., 2010; Yu, Wang, Sun, Li, & Li, 2007). Viral load is measured
at early clinic visits to aid HCV providers in determining likelihood of cure. Medication
adherence is essential throughout treatment, but particularly so during the first 12 weeks of
treatment in order to achieve these responses (Lo, III et al., 2009). Health psychologists can
assist in psychoeducation about medication adherence, development of adherence strategies,
and helping patients cope with the disappointment of not achieving early virological
response.
Adherence to the Treatment Protocol
As Figure 1 illustrates, biopsychosocial factors before and during treatment have the
potential to reduce adherence to the treatment protocol, which, in turn, lower chances for
SVR. “Adherence to the treatment protocol” has historically been defined as the actual
amount of medication taken compared to the prescribed amount, for the full duration of
treatment. Patients who are maintained on greater than 80% of IFN and 80% of RBV for
greater than 80% of the treatment duration have greater probability of achieving SVR
(McHutchison et al., 2002). Unfortunately, this 80/80/80 standard does not permit us to
differentiate between protocol deviations due to patient behaviors and decisions, and those
which are medically-necessary due to serious adverse events and safety concerns.
Distinguishing between these deviations would allow us to identify the greatest threats to
treatment efficacy and guide the development of precise interventions to overcome them.
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How well patients take their HCV medications as prescribed is critical to the success of
treatment, but has rarely been the primary outcome of interest in HCV studies. However,
studies of patients’ medication-taking behaviors will likely burgeon in the next few years
with approval of triple therapy. Dosing protease inhibitors 3–4 times a day, eight hours
apart, with 20 grams of fat is such a cumbersome dosing regimen that proper dosing may
only occur 51–65% of the time (Claxton, Cramer, & Pierce, 2001).
Execution of dosing is defined as “the extent to which patient actual dosing behavior
corresponds to the ideal dosing regimen,” and the term “missed doses” is commonly used to
describe the discrepancy between actual and ideal dosing (Urquhart & Vrijens, 2005). The
few HCV studies to report on execution of dosing suggest that patients have problems taking
their medications, the amount of medication missed increases over time, and may be enough
to impede virologic response and SVR (Alam, Stainbrook, Cecil, & Kistler, 2010; Cacoub et
al., 2008; Conjeevaram et al., 2006; Fumaz et al., 2007; Lo, III et al., 2009; Smith et al.,
2007; Weiss et al., 2008).
Understanding the role of psychological and behavioral factors that affect dosing execution
will become paramount, so that interventions can be developed to optimize SVR. Toward
this end, execution of dosing should be a primary outcome of treatment studies and should
be measured prospectively using objective methods. Patients at risk for missing doses need
to be identified. Virtually no studies exist on predictors of missed doses in HCV, so
extrapolation from HIV studies seems reasonable. Predictors of medication adherence to
HIV regimens operate at the patient (e.g., beliefs about treatment, self-efficacy, depression,
substance use, socioeconomic status, cognitive dysfunction), regimen (e.g., number and
timing of doses, side effects), provider (e.g., communication skills), and social (e.g., social
norms, support) levels (Golin et al., 2002). These same variables may predict missed doses
during HCV treatment.
Dose reductions and premature treatment discontinuations
Dose reductions are sometimes necessary to mitigate severe treatment-related side effects
but can compromise treatment efficacy. Symptom-driven dose reductions, although
generally initiated by the provider, are dose reductions that occur to manage patients’
intolerance of side effects or emotional disturbances that are problematic but not life-
threatening (e.g., irritability, tearfulness). Medically-necessary dose reductions initiated by
the provider are often out of the patient’s control (e.g., lab abnormalities, virological
nonresponse, medical disorders) and should not be counted as acts of patient nonadherence.
There are also situations where treatment is discontinued prematurely, owing to a
combination of patient behaviors, patient decisions, and provider decisions. Persistence is a
patient-level factor, defined as the total length of time a patient takes a medication, from first
dose to last dose (Urquhart & Vrijens, 2005; Vrijens, Vincze, Kristanto, Urquhart, &
Burnier, 2008). All noncompliant behaviors or decisions to prematurely stop the regimen
that are judged to be under the patients’ control are deemed acts of nonpersistence: choosing
to drop out; being lost to follow-up; not complying with physician recommendations; and
discontinuing treatment early due to intolerance of unpleasant, but not medically dangerous
side effects. In contrast, medically-necessary treatment discontinuations are due to safety
issues, are out of the patient’s control, and occur to manage lab abnormalities or medical
conditions.
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Psychological and Behavioral Intervention Research in HCV Psychological
Interventions to Cope with HCV and Treatment-related Side Effects
The management of HCV treatment side effects has been almost exclusively under the
purview of medical intervention, which is appropriate for the management of laboratory
abnormalities or other medically severe adverse side effects. However, many treatment
discontinuations and dose reductions may be due more to patients’ inability to tolerate
symptoms that interfere with life functioning. Antidepressant medications have been the
most readily available therapeutic option for HCV specialists to manage their patients’
emotional distress. However, the evidence demonstrating the efficacy of antidepressants in
ameliorating IFN-induced depression is equivocal (ez-Quevedo et al., 2011; Kraus et al.,
2008). Pharmacotherapy also has limitations (e.g., patient reluctance due to side effects,
addiction history, liver toxicity) and does not build self-efficacy or coping skills to empower
patients to self-manage symptoms.
As with other diseases, health psychologists can play an important role in attenuating
decrements in HrQOL, as well as contribute to multidisciplinary disease management. Given
that patients experience preexisting clusters of somatic/neurovegetative symptoms in the
early weeks of treatment (e.g., fatigue, insomnia, pain, headache) that lead to reduced
HrQOL and worsening depression later in treatment, multi-component psychological
interventions that treat multiple concurrent symptoms and improve overall coping skills may
be highly beneficial. Empirically-proven psychological treatments for other disease
symptoms and treatment side effects exist and can be adapted for HCV treatment (Andersen
et al., 2004; Antoni, Ironson, & Schneiderman, 2007; Given et al., 2004; Groessl et al.,
2011; Safren et al., 2009).
Several intervention frameworks hold promise for adaptation to HCV. Based on a
preexisting self-management intervention grounded in social cognitive learning theory, a
recent clinical trial found improvements in HCV knowledge, self-efficacy, and vitality/
energy in veterans not on treatment who participated in a 6-week self-management group,
compared to those who did not (Groessl et al., 2011). Given that many patients cannot or
choose not to undergo HCV treatment, self-management programs that facilitate problem-
solving skills, day-to-day management of illness, and enhancing social support may be
particularly useful for individuals learning to cope with chronic liver disease. Another
suitable intervention may be the Cognitive Behavioral Treatment for Depression and
Adherence (CBT-AD) model, which combines traditional CBT to treat depression with
motivational interviewing and problem-solving skills targeting medication adherence
(Safren et al., 2009). The CBT-AD was delivered in individual sessions with HIV+ persons
and has been shown to reduce depression post-treatment and 12 months later in patients with
refractory depression. Interventions can also be guided by the Cognitive Behavioral Stress
Management (CBSM) intervention and the Biobehavioral Intervention for Cancer Stress and
Disease (Andersen et al., 2004; Antoni et al., 2007). The CBSM is a 10-session group-based
intervention focused on stress reduction and relaxation kills, decreasing negative mood,
assertiveness and communication training, and anger management. The Biobehavioral
Intervention is also group-based and includes strategies to reduce stress (e.g., progressive
muscle relaxation), improve mood (e.g., positive coping, problem-solving), alter health
behaviors (diet, exercise, smoking cessation), and maintain treatment adherence (Andersen
et al., 2004). The group-based delivery system of these interventions makes them more cost-
effective and likely to ameliorate some of the social isolation commonly reported by HCV
patients. Given multiple similarities between HCV patients and those with HIV or cancer
undergoing medical treatments, these frameworks may be well-suited for adaptation for
HCV interventions.
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Active ingredients of other behavioral medicine protocols may need to be incorporated into
multi-component interventions to specifically target insomnia, headache, and pain. Stimulus
control, sleep hygiene, sleep restriction strategies and constructive worry techniques could
target insomnia (Edinger et al., 2009). Identification and management of triggers using daily
diaries may reduce headaches (Nicholson, Buse, Andrasik, & Lipton, 2011). Flu-like
symptoms and join pain may respond to specific pain coping skills like establishing activity-
rest cycles and learning attention diversion (Keefe et al., 1990). Helping patients acquire the
skills to manage early somatic side effects may preserve HrQOL and thwart the
development of major depression.
Integrated, Multidisciplinary Approaches for HCV Care
The Action Plan for Combating the Silent Epidemic of Viral Hepatitis consistently
emphasizes the pivotal role of integrated, multidisciplinary approaches to optimize HCV
care for patients with substance use and mental health problems (U.S.DHHS, 2011).
Integrated models of care are broadly defined as clinical strategies or interventions
“intended to improve the coordination of care and communication among caregivers,
streamline protocols for movement across the care system, co-locate services, or deploy
fully integrated service teams” (Willenbring, 2005) p. S228). Prior studies highlight a few
promising models worthy of further investigation. For instance, when HCV treatment is
provided within integrated methadone maintenance and infectious disease clinics, illicit drug
users are more able to access care, complete treatment, and achieve good SVR rates
(Grebely et al., 2010; Sylvestre et al., 2004; Sylvestre & Clements, 2007). Co-locating
mental health/addiction specialists within liver clinics is also a viable option. We
demonstrated that co-location of a psychologist employing case management and
motivational interviewing strategies with patients deferred due to active mental health and
substance use issues, improved eligibility for HCV treatment. Participants in the intervention
condition were twice as likely (42%) to be approved for treatment by providers compared to
those who received usual care (18%)(Evon et al., 2011).
With these ideas being echoed recently by other global and federal healthcare organizations,
a major paradigm shift in HCV care is anticipated that will place greater focus and resources
on the development, implementation, and evaluation of team-based disease management of
HCV. Psychologists’ considerable expertise and knowledge of the behavioral and social
sciences are needed at the table. In particular, psychologists can bring their knowledge of
implementation sciences as well as expertise in designing, conducting, and evaluating
protocols to program development. Guided by useful approaches such as Intervention
Mapping (Barthlomew, Parcel, & Kok, 2011), psychologists have much to offer those
seeking new and better ways to care for patients with HCV.
Adherence Interventions
Only three observational studies and no clinical trials of HCV adherence interventions have
been published (Cacoub et al., 2008; Marino et al., 2009; Sylvestre & Clements, 2007).
Patients (N=674) who received “therapeutic education” (support documents, educational
material, individual sessions) had higher rates of dosing IFN (78%) and RBV (70%)
compared to patients who did not receive education (69% and 56%, respectively) (Cacoub et
al., 2008). In another study, 50 patients who received ongoing pharmacist-delivered
“psychoeducation” (pharmacological and behavioral side effect management, education,
support) had dosing rates of 85.7% (Marino et al., 2009). Finally, 68% of patients receiving
HCV treatment in a multidisciplinary peer-assisted methadone clinic were described as
medically adherent (Sylvestre & Clements, 2007). These studies provide relevant
observations about the usefulness of psychoeducation, pharmacist-delivered education, and
multidisciplinary teams. However, no conclusions can be made regarding the efficacy of
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these interventions due to lack of control groups, and the putative active ingredients of these
interventions were not measured. Finally, adherence enhancement interventions for HCV
should consider using novel measurement technology and intervention delivery systems that
are being tested in other medical populations, such as smart-phone technology, interactive
voice response technology, and smart-phone video-capturing of medication-taking behaviors
(Hoffman et al., 2009; Schroder, Johnson, & Wiebe, 2007; Swendeman & Rotheram-Borus,
2010).
Research Implications: Where Can Psychology Contribute?
As highlighted throughout this review and exemplified below, clinical psychologists are
well-positioned (a) to shed light on covariates related to HCV health and treatment outcomes
to enhance knowledge and to inform clinical practice guidelines and intervention
development; and (b) to lead the development, implementation, and evaluation of
interventions and programs that will allow clinical scientists to establish evidence-based
practices and improve access to HCV care and treatment outcomes.
Where there is insufficient knowledge of psychosocial factors (e.g., alcohol use, coping
styles, stigma, reasons for missing doses) associated with HCV health and treatment
outcomes in order to inform intervention development or clinical practice, there is a
compelling need for rigorous observational, cross-sectional, and prospective studies. For
instance, improving the quantitative measurement of alcohol consumption, particularly at
the mild to moderate levels of use, and associating consumption levels with liver disease
severity, progression, and treatment outcomes is greatly needed to establish evidence-based
clinical guidelines and tailor interventions for specific cohorts of drinkers. Similarly, the
impact of illicit substance use behaviors (i.e., drug type, frequency, duration, quantity) on
treatment outcomes is also needed to inform clinical practice, such as helping providers
select reasonable treatment candidates. As healthcare providers’ beliefs and attitudes about
treating patients with co-occurring alcohol or drug use partly determine who gains access to
HCV treatment, understanding provider beliefs and attitudes could inform strategies to
improve adherence to national guidelines and empirically-based best practices. Finally, it
behooves researchers to measure and evaluate separately factors that decrease adherence to
treatment protocols, and to distinguish between medically-necessary and patient-driven
factors. Deviations from the protocol that threaten treatment efficacy may be related to
different patient characteristics (moderators), occur for different reasons (mechanisms), have
different clinical consequences, and therefore will require markedly different intervention
tactics.
Where there is a clear and pressing need or sufficient evidence to support intervention
research, psychologists can lead the development and evaluation of interventions to improve
HCV health and treatment outcomes. Consistent with recent federal agency
recommendations, examining integrated and/or multidisciplinary disease management
models for patients with comorbid mental health, alcohol, and drug addiction is drastically
needed (U.S.DHHS, 2011). In clinical practices where integrated care models are less
feasible, programs that train medical providers to deliver brief screening and interventions to
reduce alcohol and drug use are being called for (U.S.DHHS, 2011). Studies testing
interventions to enhance adherence to HCV treatment regimens and optimize dose-taking
behaviors, with an emphasis on identifying mechanisms and use of cutting-edge web-based,
telehealth, and smart-phone technology for measurement and intervention delivery, can
point to new directions to improve health outcomes.
Psychological interventions to cope with HCV disease and treatment-related side effects are
needed. Delivery of a skill-building period prior to initiating HCV treatment, followed by
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maintenance sessions during treatment, may be more effective in stabilizing premorbid HCV
symptoms and improving tolerance of treatment-related side effects. Cognitive and
behavioral strategies should target somatic side effects first (e.g., fatigue, insomnia, pain) to
stymie transition into later cognitive/affective depressive symptoms and worsening of
HrQOL (Robaeys et al., 2007; Wichers et al., 2005). Group-based interventions may be
ideal to reduce social isolation, minimize stigma, and build peer support; these nonspecific
therapeutic group processes may enhance intervention outcomes. Finally, studies should
explore the effects of psychological interventions on physiological markers (e.g., immune
functioning, virological response), as well as the cost-effectiveness and sustainability of
such interventions.
Concluding Comments
Optimal care for individuals with HCV will entail knowledge of and interventions for
infectious disease prevention, screening, management of comorbid psychological and
addiction disorders, HrQOL, racial disparities, stigma, access to care, treatment adherence,
and disease- and treatment-related side effects. Clinical psychologists can greatly contribute
to having an impact on HCV care and treatment in real-world settings by engaging in
multidisciplinary team science and clinical practice aimed at reducing the individual, public,
and economic burden of HCV. To have such an impact, clinical psychologists need to forge
new partnerships with gastroenterologists and hepatologists, many of whom may be
unfamiliar with the many ways that clinical health psychologists and behavioral medicine
experts can greatly enhance patient care through evidence-based practices. While medical
providers may be keenly aware of the inherent psychosocial and behavioral challenges that
interfere with optimal HCV management and treatment, they may not realize that clinical
psychologists are also behavioral and social scientists, equipped to help them and their
patients to better manage symptoms and treatment side effects, cope with stigma, stress, and
mental health issues, and make requisite lifestyle changes. Clinical psychologists are
encouraged to consider expansion and application of their expertise to the field of
hepatology, where only a few from our discipline are currently represented, to develop a
new interdisciplinary field of psycho-hepatology which can more broadly focus on
biopsychosocial aspects of chronic liver diseases.
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